Ambrx Revenue and Competitors
Estimated Revenue & Valuation
- Ambrx's estimated annual revenue is currently $12.3M per year.
- Ambrx's estimated revenue per employee is $79,484
- Ambrx's total funding is $346M.
- Ambrx's current valuation is $213.2M. (January 2022)
Employee Data
- Ambrx has 155 Employees.
- Ambrx grew their employee count by 32% last year.
Ambrx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, Pharmacovigilance | Reveal Email/Phone |
2 | SVP | Reveal Email/Phone |
3 | VP and Head Chemistry | Reveal Email/Phone |
4 | Chief Scientific Officer | Reveal Email/Phone |
5 | Director, Clinical Science, Medical Writing, and Publications | Reveal Email/Phone |
6 | Director Clinical Science and Biomarkers | Reveal Email/Phone |
7 | Executive Director Pharmaceutical and Analytical Development, Drug Product Manufacturing Oversight | Reveal Email/Phone |
8 | Chief Operating Officer | Reveal Email/Phone |
9 | Director - Upstream Process Development | Reveal Email/Phone |
10 | Director, Protein Sciences and Downstream Process Development | Reveal Email/Phone |
Ambrx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Ambrx?
Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties. By combing the versatility of medicinal chemistry with modern biotechnology, Ambrx is transforming the field of protein-based medicines. Ambrx completed a $12.5 million Series A preferred stock financing from investors including 5AM Ventures and Tavistock Life Sciences. Ambrx is based in San Diego, California and is currently recruiting a world-class scientific and commercialization team.
keywords:Biotechnology
$346M
Total Funding
155
Number of Employees
$12.3M
Revenue (est)
32%
Employee Growth %
$213.2M
Valuation
N/A
Accelerator
Ambrx News
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code ... for drug candidates generated using Ambrx technology.
SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Gary Yeung, CFA, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Yeung brings extensive leadership experience in raising capital, building biotech companies, and leading organizations to deve ...
Investors in the $200 million round include Fidelity Management & Research Co., Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners and Suvretta Capital Management, as well as funds and accounts managed by BlackRock. Ambrx also has struck partnerships with larg ...
San Diego-based biopharmaceuticals developer Ambrx has raised $200M in a funding round, according to the company, which included Fidelity Management & Research Company LLC, funds and accounts managed by BlackRock, Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partn ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $31.2M | 155 | 8% | N/A |
#2 | $46M | 155 | N/A | N/A |
#3 | $55.4M | 155 | 8% | N/A |
#4 | $20.5M | 155 | 1% | N/A |
#5 | $34.2M | 156 | 0% | $75.9M |